Monte Rosa Therapeutics Profit Margin

The latest profit margin for GLUE is -560.85% as of June 2026. That compares with 13.58% in the prior-year period — down 4230.4% year over year. That is below the Healthcare sector average of 13.89%. Investors often review this figure alongside Monte Rosa Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, GLUE's profit margin moved from 13.58% to -560.85% — a 4230.4% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Monte Rosa Therapeutics's valuation or profitability profile.

Against Healthcare companies, GLUE currently prints -560.85% for profit margin, while the sector average sits near 13.89%. That is roughly 4136.9% below the sector mean. Large gaps often invite a closer look at Monte Rosa Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Monte Rosa Therapeutics converts resources into returns. At -560.85%, GLUE may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 13.58% in the prior-year period — down 4230.4% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting GLUE's profit margin (-560.85%), review year-over-year change from 13.58%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.